JO
RYTM icon

John Overdeck’s Rhythm Pharmaceuticals RYTM Stock Holding History

John Overdeck’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$511K Buy
4,600
+300
+7% +$27.1K ﹤0.01% 4146
2026
Q1 		$374K Buy
+4,300
New +$418K ﹤0.01% 3920
2021
Q4 		– Sell
-22,306
Closed -$291K – 4808
2021
Q3 		$291K Sell
22,306
-34,772
-61% -$531K ﹤0.01% 3695
2021
Q2 		$1.12M Sell
57,078
-237,582
-81% -$4.93M ﹤0.01% 2382
2021
Q1 		$6.27M Buy
294,660
+270,979
+1,144% +$7.86M 0.02% 926
2020
Q4 		$704K Buy
23,681
+1,939
+9% +$49.3K ﹤0.01% 2255
2020
Q3 		$471K Buy
+21,742
New +$498K ﹤0.01% 2293
2020
Q1 		– Sell
-41,922
Closed -$963K – 3734
2019
Q4 		$963K Buy
+41,922
New +$931K ﹤0.01% 2216
2019
Q3 		– Sell
-11,500
Closed -$253K – 3744
2019
Q2 		$253K Sell
11,500
-2,629
-19% -$66.4K ﹤0.01% 2956
2019
Q1 		$387K Buy
+14,129
New +$406K ﹤0.01% 2431

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

John Overdeck's RYTM Position: Q2 2026 in Review

John Overdeck increased its Rhythm Pharmaceuticals (RYTM) stake by 7% in Q2 2026, buying an estimated $27.1K and bringing the position to 4,600 shares worth $511K. The position accounts for ﹤0.01% of the portfolio, ranked #4146.

John Overdeck first reported a position in RYTM in Q1 2019 and has held it in 10 quarters since. The position peaked at $6.27M in Q1 2021. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • John Overdeck held 4,600 shares of Rhythm Pharmaceuticals worth $511K as of Q2 2026.
  • John Overdeck bought 300 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $27.1K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4146 holding.
  • John Overdeck first reported a position in Rhythm Pharmaceuticals in Q1 2019 and has held it in 10 quarters since.
  • John Overdeck's Rhythm Pharmaceuticals position peaked at $6.27M in Q1 2021.
  • 300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.